Related Experiment Video
Updated: May 19, 2026
14:57
Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
Mitotic Kinases and p53 Signaling.
Geun-Hyoung Ha1, Eun-Kyoung Yim Breuer
1Department of Radiation Oncology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA.
Biochemistry Research International
|August 2, 2012
Summary
Errors in mitosis, crucial for cell division, can cause cancer. Understanding the network between mitotic kinases and p53 signaling is key to improving cancer therapies targeting these pathways.
Area of Science:
- Cell Biology
- Molecular Oncology
- Cancer Therapeutics
Background:
- Mitosis is a tightly regulated process; errors lead to aneuploidy, genomic instability, and cancer.
- Mitotic kinase deregulation is linked to cell division errors and aneuploidy, making them cancer targets.
- Current mitotic kinase inhibitors face challenges in safety and patient selection for cancer therapy.
Purpose of the Study:
- To explore the molecular mechanisms of mitotic kinase signaling and its interactive network.
- To investigate the central role of tumor suppressor p53 within the mitotic kinase signaling network.
- To provide insights for overcoming limitations in targeting mitotic kinases for improved cancer treatment outcomes.
Main Methods:
- Literature review and analysis of existing research on mitotic kinase signaling pathways.
- Examination of the interplay between mitotic kinases and p53 in response to mitotic spindle damage.
- Exploration of mutual regulatory mechanisms between mitotic kinases and p53 signaling.
Main Results:
- Mitotic kinase signaling is crucial for proper cell division; its deregulation contributes to aneuploidy and tumorigenesis.
- Tumor suppressor p53 is centrally positioned in the mitotic kinase signaling network.
- Evidence indicates a mutual regulatory network between mitotic kinases and p53 signaling, involving phosphorylation and gene expression modulation.
Conclusions:
- Deciphering the regulatory network between mitotic kinases and p53 is essential for advancing cancer therapy.
- Understanding this network can help overcome safety and patient selection issues associated with current mitotic kinase inhibitors.
- Targeting the mitotic kinase-p53 network holds promise for improving the efficacy of cancer treatments.
Related Concept Videos
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
02:36DNA Damage Can Stall the Cell Cycle
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
02:36DNA Damage can Stall the Cell Cycle
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...